Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Sep 14, 2009; 15(34): 4278-4283
Published online Sep 14, 2009. doi: 10.3748/wjg.15.4278
Published online Sep 14, 2009. doi: 10.3748/wjg.15.4278
Table 3 Observed toxicity according NCI-CTC grading (n = 12)
| NCI-CTC grade | ||||
| 1 | 2 | 3 | 4 | |
| Hematological | ||||
| Anemia | 1 | 3 | ||
| Leucopenia | 2 | 4 | ||
| Neutropenia | 2 | 4 | ||
| Thrombocytopenia | 1 | 2 | ||
| Non hematological | ||||
| Nausea/vomiting | 2 | 5 | ||
| Mucositis | 3 | 4 | 2 | |
| Diarrhea | 5 | 2 | ||
| Proteinuria | 1 | |||
| Asthenia | 3 | 5 | ||
| High blood pressure | 3 | |||
- Citation: Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283
- URL: https://www.wjgnet.com/1007-9327/full/v15/i34/4278.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.4278